摘要
目的探究乳铁蛋白胶囊与孟鲁司特钠联用治疗反复下呼吸道感染患儿的疗效及其对气道炎症、体液免疫、细胞免疫的影响。方法回顾性选取2018年3月至2020年1月于我院治疗的反复下呼吸道感染患儿108例作为研究对象,按照治疗方案不同分两组,各54例。两组均给予常规治疗,在此基础上,对照组给予孟鲁司特钠,观察组同时给予乳铁蛋白胶囊与孟鲁司特钠。比较两组临床症状体征改善情况、治疗前后气道炎症因子[诱导痰嗜酸性粒细胞(eosinophil,EOS)、血清降钙素原(procalcitonin,PCT)、C反应蛋白(C-reactiveprotein,CRP)、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)]、体液免疫[免疫球蛋白A(Immunoglobulin A,IgA)、免疫球蛋白G(immunoglobulin G,IgG)、免疫球蛋白M(immunoglobulin M,IgM)]、细胞免疫[T淋巴细胞亚群(CD4^(+)、CD3^(+)、CD8^(+)、CD4^(+)/CD8^(+))]及不良反应发生率。结果观察组总有效率92.59%显著高于对照组75.93%(P<0.05);观察组退热时间、咳嗽消失时间、肺部啰音消失时间、住院时间显著短于对照组(P<0.05);治疗1个疗程、2个疗程、3个疗程后,观察组诱导痰EOS,血清PCT、CRP、TNF-α显著低于对照组(P<0.05),血清IgA、IgG、IgM显著高于对照组(P<0.05),CD4^(+)、CD3^(+)、CD4^(+)/CD8^(+)显著高于对照组,CD8^(+)显著低于对照组(P<0.05);观察组不良反应发生率(11.11%)与对照组(14.82%)比较,差异无统计学意义(P>0.05)。结论乳铁蛋白胶囊与孟鲁司特钠联用治疗反复下呼吸道感染患儿疗效确切,可有效缓解其临床症状体征,减轻气道炎症反应,改善细胞免疫、体液免疫状态,安全可靠,值得临床推广应用。
Objective To explore the efficacy in the treatment of children with recurrent lower respiratory tract infections and effects on airway inflammation,humoral immunity,and cellular immunity of the combination of lactoferrin capsules and montelukast sodium.Methods 108 children with recurrent lower respiratory tract infections admitted to our hospital from March 2018 to January 2020 were retrospectively selected as the research objects.They were divided into two groups according to different treatment plans(54 cases in each group).Both groups were given conventional treatment.And the control group was given montelukast sodium,the observation group was given lactoferrin capsules and montelukast sodium.The improvement of clinical symptoms and signs,airway inflammation[including induced sputum eosinophils(EOS),serum procalcitonin(PCT),C-reactive protein(CRP),tumor necrosis factor-α(TNF-α)],humoral immunity[including immunoglobulin A(IgA),immunoglobulin G(IgG),immunoglobulin M(IgM)],cellular immunity[T lymphocyte subsets(CD4^(+),CD3^(+),CD8^(+),CD4^(+)/CD8^(+))]before and after treatment and the incidence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 92.59%higher than 75.93%in the control group significantly(P<0.05).The antipyretic time,cough disappearance time,lung rale disappearance time and hospital stay of the observation group were shorter than those of the control group significantly(P<0.05).The induced sputum EOS,serum PCT,CRP and TNF-αin the observation group were lower than those in the control group significantly(P<0.05),serum IgA,IgG and IgM in the observation group were higher than those in the control group significantly(P<0.05),CD4^(+),CD3^(+),CD4^(+)/CD8^(+)in the observation group were higher than the control group significantly(P<0.05),and CD8^(+)was lower than that of the control group significantly(P<0.05)after 1 course,2 courses and 3 courses of treatment.There was no significant difference in the incidence of adverse reactions between 11.11%in the observation group and 14.82%in the control group(P>0.05).Conclusion The combination of lactoferrin capsules and montelukast sodium is effective in treating children with recurrent lower respiratory tract infections.It can effectively relieve its clinical symptoms and signs,reduce airway inflammation,improve cellular immunity and humoral immunity,and is safe and reliable.It is worthy of clinical application.
作者
赵天兰
任盛
ZHAO Tianlan;REN Sheng(Mianyang People’s Hospital,Mianyang,Sichuan 621000,China)
出处
《中国优生与遗传杂志》
2021年第8期1115-1120,共6页
Chinese Journal of Birth Health & Heredity
关键词
反复下呼吸道感染
乳铁蛋白胶囊
孟鲁司特钠
气道炎症
体液免疫
repeated lower respiratory tract infections
lactoferrin capsules
montelukast sodium
airway inflammation
humoral immunity
